# PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

> **NCT05447637** · — · COMPLETED · sponsor: **Invitae Corporation** · enrollment: 1000 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Invitae multi-cancer gene panel

## Key facts

- **NCT ID:** NCT05447637
- **Lead sponsor:** Invitae Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2022-05-31
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447637, "PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05447637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*